Flag of the European Union EU Clinical Trials Register Help

Clinical trials for EPCAM

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: EPCAM. Displaying page 1 of 1.
    EudraCT Number: 2005-001700-39 Sponsor Protocol Number: IP-REM-PK-01-EU Start Date*: 2005-09-14
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Determination of systemic exposure and characterization of pharmacokinetics of the tri-functional antibody catumaxomab (anti-EpCAM X anti-CD3) administered intraperitoneally in EpCAM positive cance...
    Medical condition: epithelial cell adhesion molecule (EpCAM) expressing tumors in patients with malignant ascites requiring therapeutic ascites puncture
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025538 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000723-15 Sponsor Protocol Number: IP-REM-AC-01 inc. A1,D1,2,3,4,5; Start Date*: 2004-11-15
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Two-arm, randomized (2:1), open-label phase II/III study in EpCAM positive cancer patients with symptomatic malignant ascites using paracentesis plus the tri-functional antibody removab (anti-EpCAM...
    Medical condition: Cancer : Malignant Ascites
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025538 Malignant ascites LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) GB (Completed) EE (Completed) LV (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022810-26 Sponsor Protocol Number: PERCAT01 Version 10, 31.01.2011 Start Date*: 2011-03-16
    Sponsor Name:University Witten/Herdecke
    Full Title: MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CH...
    Medical condition: PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    12.1 10068069 Peritoneal carcinomatosis LLT
    12.1 10052360 Colorectal adenocarcinoma LLT
    12.1 10017758 Gastric cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005945-20 Sponsor Protocol Number: IP-REM-GC-02 Start Date*: 2006-06-08
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Multicenter, open-label and randomized phase II study to evaluate safety and efficacy of the tri-functional bispecific antibody catumaxomab(anti-EpCAM x anti-CD3) in patients after curative resecti...
    Medical condition: Advanced gastric adenocarcinoma and intended curative gastrectomy (R0 resection).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017812 Gastric neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003201-14 Sponsor Protocol Number: ERTUSO Start Date*: 2012-03-02
    Sponsor Name: Krankenhaus Nordwest GmbH
    Full Title: Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-...
    Medical condition: Patients with HER2/neu (1+/SISH positive, 2+ and 3+) expressing solid tumors that are progressing after standard therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002727-16 Sponsor Protocol Number: IP-CAT-GC-03 Start Date*: 2007-03-06
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Multicenter, open-label phase II study to evaluate the safety and efficacy of the tri-functional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with gastric adenocarcinoma afte...
    Medical condition: Gastric Neoplasm malignant
    Disease: Version SOC Term Classification Code Term Level
    15.0 10017947 - Gastrointestinal disorders 10017812 Gastric neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000560-28 Sponsor Protocol Number: ImmunoPeCa Start Date*: 2014-07-24
    Sponsor Name:Oslo University Hospital
    Full Title: PHASE I/II TRIAL OF MOC31PE IMMUNOTOXIN IN PERITONEAL CARCINOMATOSIS FROM COLORECTAL CARCINOMA.
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003548-35 Sponsor Protocol Number: MesaCAPP Start Date*: 2017-03-10
    Sponsor Name:Medical University of Vienna
    Full Title: Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome
    Medical condition: Colorectal Cancer Prevention in Lynch syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10051981 Lynch syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003011-55 Sponsor Protocol Number: MesaCAPP Start Date*: 2020-07-23
    Sponsor Name:Karolinska Institute
    Full Title: Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
    Medical condition: Lynch Syndrome, which is increasing the risk of developing colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051981 Lynch syndrome LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018478-19 Sponsor Protocol Number: GEICO-1001 Start Date*: 2010-06-07
    Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario - GEICO
    Full Title: Ensayo fase II para evaluar la eficacia y seguridad de catumaxomab como tratamiento de consolidación en pacientes con un cáncer epitelial de ovario en una segunda o tercera remisión completa
    Medical condition: eficacia y seguridad de catumaxomab como tratamiento de consolidación en pacientes con un cáncer epitelial de ovario en una segunda o tercera remisión completa
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005352-41 Sponsor Protocol Number: TACT-2C-TRIAL Start Date*: 2014-09-05
    Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI CREMONA
    Full Title: A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 pos...
    Medical condition: Metastatic Breast Cancer in HER2- positive CTC with primary HER2-negative.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004566-13 Sponsor Protocol Number: EMR62206-017 Start Date*: 2007-03-06
    Sponsor Name:MERCK KGaA
    Full Title: An open-label, randomised, phase II study in subjects with extensive disease, small cell lung cancer (ED-SCLC) after an initial response (complete response or partial response) to platinum-based th...
    Medical condition: extensive disease, small cell lung cancer (ED-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041071 Small cell lung cancer stage unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-004484-54 Sponsor Protocol Number: IP-CAT-OC-02 Start Date*: 2007-08-30
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer
    Medical condition: Epithelial Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033162 Ovarian epithelial cancer stage II LLT
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    9.1 10033164 Ovarian epithelial cancer stage IV LLT
    9.1 10033161 Ovarian epithelial cancer stage I LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001361-27 Sponsor Protocol Number: ICR-CTSU/2015/10054 Start Date*: 2016-09-21
    Sponsor Name:The Institute of Cancer Research
    Full Title: CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer.
    Medical condition: Advanced Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001198 Adenocarcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024111-13 Sponsor Protocol Number: AIO-STO-0110 Start Date*: 2011-04-15
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy
    Medical condition: Gastric adenocarcinoma and carcinoma of the esophago-gastric junction (type II and type III according to Siewert’s classification) prior to gastrectomy, with peritoneal carcinomatosis.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068069 Peritoneal carcinomatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001557-17 Sponsor Protocol Number: IP-CAT-AC-03 Start Date*: 2008-12-16
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Two-arm, randomized, open-label, phase IIIb study investigating the safety of a 3 hour i.p. infusion of catumaxomab with and without prednisolone premedication in patients with malignant ascites du...
    Medical condition: malignant ascites
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025538 Malignant ascites PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) FR (Ongoing) BE (Completed) GB (Completed) SE (Completed) NL (Ongoing) DK (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000411-14 Sponsor Protocol Number: 6639 Start Date*: 2014-07-17
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological misma...
    Medical condition: Lynch Syndrome also known as HNPCC (non hereditary non polyposis colorectal cancer).
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10051981 Lynch syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FI (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014076-22 Sponsor Protocol Number: IP-CAT-AC-04 Start Date*: 2009-09-23
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after...
    Medical condition: Malignant Ascites
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025538 Malignant ascites PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Ongoing) IT (Completed) BE (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003289-18 Sponsor Protocol Number: 219369 Start Date*: 2023-03-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer
    Medical condition: Untreated Stage II/III dMMR/MSI-H locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 12:15:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA